Key result
~26% of doxorubicin-treated sarcoma survivors harbor three or more modifiable CAD risk factors.
Why the study?
Risk factors for CAD are often preventable or treatable, but their distribution needed characterization in sarcoma survivors treated with doxorubicin.
Cohort (n=61)
No
Sarcoma survivors treated with doxorubicin have a high burden of modifiable CAD risk factors, highlighting the need for targeted survivorship care and evidence-based guidelines.
May warrant CAD risk screening in doxorubicin-treated sarcoma survivors; hypothesis-generating for targeted interventions pending prospective trials.
AIM: .) are well known for CAD and can be often prevented or treated, thus reducing the risk of CAD in these patients. We piloted a risk-based survivorship clinic in an academic medical center to characterize the distribution of risk factors for CAD and improve the quality of life in a population of sarcoma survivors treated with doxorubicin. METHODS: ) and at least 2 years post-therapy attending the sarcoma survivorship clinic. We collected clinical, demographic data, and patient reported outcomes via PROMIS questionnaires annually. RESULTS: We demonstrated a high burden of chronic diseases in this population. Among six chronic conditions that are known risk factors for CAD (hypertension, diabetes, obesity, chronic inflammation, kidney disease and dyslipidemia), more than one-fourth (26%, 16/61) of patients had three or more of these risk factors at baseline visit, and 49% (30/61) had two or more. CONCLUSION: The results of this pilot study support the presence of modifiable CAD risk factors in this population of sarcoma survivors. Evidence-based guidelines for high-risk survivors of rare cancers are needed.
No takes yet. Share an insight, caveat, or question.
Baker et al. (2020) conducted a cohort in Sarcoma survivors treated with doxorubicin (n=61). Anthracycline chemotherapy (doxorubicin) was evaluated on Presence of three or more CAD risk factors at baseline. Among adult sarcoma survivors treated with doxorubicin, 26% had three or more and 49% had two or more modifiable risk factors for coronary artery disease at baseline.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: